Rational design of central selective acetylcholinesterase inhibitors by means of a "bio-oxidisable prodrug" strategy

Organic and Biomolecular Chemistry

Volumn 7, Issue 12, 2009, Pages 2612-2618

  Bohn, Pierre ^a,b   Le Fur, Nicolas ^a   Hagues, Guillaume ^b   Costentin, Jean ^b   Torquet, Nicolas ^b   Papamicaël, Cyril ^a   Marsais, Francis ^a   Levacher, Vincent ^a  

^a UNIVERSITÉ ET INSA DE ROUEN   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ACTIVATION STEPS; ANIONIC SITE; BIOLOGICAL EVALUATION; CHEMICAL TOOLS; DIHYDROQUINOLINE; IN-VITRO; IN-VITRO ASSAYS; IN-VIVO; INHIBITORY ACTIVITY; POSITIVE CHARGES; PRODRUG; RATIONAL DESIGN; RIVASTIGMINE; SIDE EFFECT;

BINDING SITES; CATALYTIC OXIDATION; SALTS;

STRATEGIC PLANNING;

ACETYLCHOLINESTERASE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; PRODRUG; QUINOLINE; QUINOLINE DERIVATIVE; RIVASTIGMINE;

ARTICLE; BLOOD BRAIN BARRIER; CHEMISTRY; DRUG DESIGN; ENZYME SPECIFICITY; HUMAN; IC 50; METABOLISM; OXIDATION REDUCTION REACTION; SYNTHESIS;

ACETYLCHOLINESTERASE; BLOOD-BRAIN BARRIER; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; OXIDATION-REDUCTION; PHENYLCARBAMATES; PRODRUGS; QUINOLINES; SUBSTRATE SPECIFICITY;

EID: 67650478397     PISSN: 14770520     EISSN: None     Source Type: Journal    
DOI: 10.1039/b903041g     Document Type: Article

References (36)

1. S. O. Bachurin Med. Res. Rev. 2003 23 48
2. J. C. Jaen R. E. Davis Curr. Opin. Investig. Drugs 1993 363
3. L. Parnetti U. Senin P. Mecocci Drugs 1997 53 752
4. J. Hardy D. J. Selkoe Science 2002 297 353
5. C. L. Master R. Cappai K. J. Barnham V. L. Villemagne J. Neurochem. 2006 97 1700
6. J. M. Palacios R. Spiegel Prog. Brain Res. 1986 70 485
7. J. L. Signoret A. Whitley F. Lhermitte Lancet 1978 2 837
8. H. Wesseling S. Agoston N. Engl. J. Med. 1984 310 988
9. H. Ohjimi K. Kushiku H. Yamada T. Kuwahara Y. Kohno T. Furukawa J. Pharmacol. Exp. Ther. 1994 268 396
10. M. R. Farlow J. L. Cummings Am. J. Med. 2007 120 388
11. K. L. Davies P. Powchik Lancet 1995 345 625
12. S. L. Rogers M. R. Farlow R. S. Doody R. Mohs L. T. Friedhoff Neurology 1998 50 136
13. E. L. Barner S. L. Gray Ann. Pharmacother. 1998 32 70
14. H. M. Bryson P. Benfield Drugs Aging 1997 10 234
15. M. D. Gottwald R. I. Rozanski Expert Opin. Investig. Drugs 1999 8 1673
16. M. R. Farlow M. L. Lilly BMC Geriatrics 2005 5 3
17. C. M. Spencer S. Noble Drugs Aging 1998 13 391
18. J. J. Sramek E. J. Frackiewicz N. R. Cutler Expert Opin. Investig. Drugs 2000 9 2393
19. J. Marco-Contelles M. C. Carreiras C. Rodriguez M. Villarroya A. G. Garcia Chem. Rev. 2006 106 116
20. C. Guillou J.-L. Beunard E. Gras C. Thal Angew. Chem. Int. Ed. 2001 40 4745
21. Alan. L. Harvey Pharmac. Ther. 1995 68 113
22. A. Burns R. Bernabei R. Bullock A. J. Cruz Jentoft L. Frölich C. Hock M. Raivio E. Triau M. Vandewoude A. Wimo E. Came B. Van Baelen Gerry L. Hammond Joop C. van Oene S. Schwalen The Lancet Neurology 8 39
23. The concept of "bio-oxidisable prodrug" for the development of central selective AChE inhibitors is patented. F. Marsais, P. Bohn, V. Levacher, and N. Le Fur, PCT Int. Appl., WO, 103120, 2006
24. R. J. Kitz S. Ginsburg I. B. Willson Biochem. Pharmacol. 1967 16 2201
25. L. Prokai K. Prokai-Tatrai N. Bodor Med. Res. Rev 2000 20 367
26. N. Bodor L. Prokai Drug Discov. Today 2002 7 766
27. L. Prokai K. Prokai-Tatrai A. D. Zharikova V. Nguyen P. Perjesi Jr. S. M. Stevens J. Med. Chem. 2004 47 6025
28. P. Chen N. Bodor W.-M. Wu L. Prokai J. Med. Chem. 1998 41 3773
29. N. Bodor E. Shek T. Higuchi Science 1975 190 155
30. M. Lochner L. Mu W.-D. Woggon Adv. Synth. Catal. 2003 345 743
31. P. Charpentier V. Lobregat V. Levacher G. Dupas G. Quéguiner J. Bourguignon Tetrahedron Lett. 1998 39 4013
32. A. Basha M. Lipton S. M. Weinreb Tetrahedron Lett. 1977 48 4171
33. G. Blankenhorn E. G. Moore J. Am. Chem. Soc. 1980 102 1092
34. C. Vitry J.-L. Vasse G. Dupas V. Levacher G. Queguiner J. Bourguignon Tetrahedron 2001 57 3087
35. G. L. Ellman K. D. Courtney, Jr. V. Andres R. M. Featherstone Biochem. Pharmacol. 1961 7 88
36. T. L. Rosenberry J. M. Richardson Biochemistry 1977 16 3550